Catalyst Event
Gilead Sciences Inc (GILD) · Other
From Akros U.S. Tech 100 Index (AUT100)
6/2/2026, 12:00:00 AM
The Phase 3 IDEAL study of Livdelzi (seladelpar) met its primary endpoint on June 2, 2026. This clinical success is estimated to have a ≥5% price impact, scheduled.
Korean Translation
2026년 6월 2일, 리브델지의 3상 IDEAL 연구가 주요 평가변수를 충족함. 주요 파이프라인의 임상 성공으로 5% 이상의 주가 영향이 예상되어 'Medium'으로 분류함, 예정됨.
Related Recent Events
Microchip Technology Inc (MCHP) · Earnings Release
Next quarterly earnings for Q1 2027 are expected to be released around August 6, 2026, expected. Low impact is estimated as this is a routine scheduling announcement.
8/6/2026, 12:00:00 AM
AppLovin Corporation (APP) · Earnings Release
AppLovin's Q2 2026 earnings release is expected around August 5, 2026, based on past reporting schedules expected. Low impact estimated as the announcement of a date typically precedes the actual market-moving results.
8/5/2026, 12:00:00 AM
Advanced Micro Devices Inc (AMD) · Earnings Release
Q2 2026 earnings release and conference call scheduled.
8/4/2026, 12:00:00 AM
Cummins Inc. (CMI) · Earnings Release
Q2 2026 earnings release on 2026-08-04, for which high importance is estimated due to potential 10% price impact, is scheduled.
8/4/2026, 12:00:00 AM
KLA Corp (KLAC) · Earnings Release
Fiscal Q4 2026 earnings release on July 30, 2026, is expected to have a medium importance impact on the stock price, scheduled.
7/30/2026, 12:00:00 AM
Apple Inc (AAPL) · Earnings Release
Apple's Q3 2026 earnings release is expected on July 30, 2026; analysts forecast an EPS of approximately $1.86 forecasted. Low importance is estimated as the market impact is expected to be around 1%.
7/30/2026, 12:00:00 AM